Mortality and cause of death in mucopolysaccharidosis type II—a historical review based on data from the Hunter Outcome Survey (HOS)-Reference-Cited by-同舟云学术

Mortality and cause of death in mucopolysaccharidosis type II—a historical review based on data from the Hunter Outcome Survey (HOS)

Published:2009-07-14 Issue:4 Volume:32 Page:534-543
ISSN:0141-8955
Container-title:Journal of Inherited Metabolic Disease
language:en
Short-container-title:J Inherit Metab Dis

Author:

Jones S. A., ,Almássy Z.,Beck M.,Burt K.,Clarke J. T.,Giugliani R.,Hendriksz C.,Kroepfl T.,Lavery L.,Lin S.-P.,Malm G.,Ramaswami U.,Tincheva R.,Wraith J. E.

Publisher

Wiley

Subject

Genetics(clinical),Genetics

Link

http://www.springerlink.com/index/pdf/10.1007/s10545-009-1119-7

Reference23 articles.

1. Baehner F, Schmiedeskamp C, Krummenauer F, et al (2005) Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 28:1011–1017. doi: 10.1007/s10545-005-0112-z

2. Beck M, Ricci R, Widmer U, et al (2004) Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 34:838–844. doi: 10.1111/j.1365-2362.2004.01424.x

3. Cudry S, Tigaud I, Froissart R, Bonnet V, Maire I, Bozon D (2000) MPS II in females: molecular basis of two different cases. J Med Genet 37:E29. doi: 10.1136/jmg.37.10.e29

4. Eng CM, Fletcher J, Wilcox WR, et al (2007) Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 30:184–192. doi: 10.1007/s10545-007-0521-2

5. Hopkin RJ, Bissler J, Banikazemi M, et al (2008) Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res 64:550–5.

Cited by 135 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Health service utilization, economic burden and quality of life of patients with mucopolysaccharidosis in China;Orphanet Journal of Rare Diseases;2024-09-06

2. Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond;BioDrugs;2024-08-23

3. Long‐term cardiovascular outcomes and mortality with enzyme replacement therapy in patients with mucopolysaccharidosis type II;Journal of Inherited Metabolic Disease;2024-07-30

4. Causes of death in mucopolysaccharidoses;Molecular Genetics and Metabolism;2024-07

5. Caregiver experiences and observations of intrathecal idursulfase-IT treatment in a phase 2/3 trial in pediatric patients with neuronopathic mucopolysaccharidosis II;Orphanet Journal of Rare Diseases;2024-03-10